Annotation Detail
Information
- Associated Genes
- MMP9
- Associated Variants
-
MMP9 SERUM LEVELS
MMP9 SERUM LEVELS - Associated Disease
- inflammatory breast carcinoma
- Source Database
- CIViC Evidence
- Description
- MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low bMMP9 was correlated with better OS (p=0.022) and non-significantly associated with longer DFS (p=0.071). Correlation to DFS was also found after multivariate analysis (p=0.041, HR: 3.511). bMMP9 was associated with death (p=0.035). During treatment, a significant decrease in MMP9 levels (p<0.001) was observed in 87% of patients.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1157
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3553
- Variant URL
- https://civic.genome.wustl.edu/links/variants/488
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Inflammatory Breast Carcinoma
- Evidence Direction
- Supports
- Drug
- Bevacizumab
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 26921265
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Bevacizumab | Resitance or Non-Reponse | true |